Multiple Endocrine Neoplasia Type 2 Market

Market Overview:

The 7 major multiple endocrine neoplasia type 2 markets reached a value of USD 1,369.6 Million in ​2024​. Looking forward, IMARC Group expects the 7MM to reach USD 2,988.7 Million by 2035, exhibiting a growth rate (CAGR) of 7.38% during ​2025-2035​.

The multiple endocrine neoplasia type 2 market has been comprehensively analyzed in IMARC's new report titled "Multiple Endocrine Neoplasia Type 2 Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast ​2025-2035​". MEN2 is an uncommon, inherited condition resulting from mutations of the RET proto-oncogene, which is responsible for causing endocrine tumors. It occurs in two subtypes, MEN2A and MEN2B, with MEN2A causing medullary thyroid carcinoma (MTC), pheochromocytomas, and hyperparathyroidism, whereas MEN2B is an aggressive form presenting with early-onset MTC, mucosal neuromas, and a marfanoid habitus. It mainly involves the thyroid, adrenal, and parathyroid glands, causing potentially life-threatening complications if untreated. The presentation depends on tumor location and growth but typically includes thyroid nodules, neck swelling, hypertension from pheochromocytoma, hyperhidrosis, palpitations, hypercalcemia, and neuromuscular disturbances. Diagnosis is dependent upon genetic evaluation for RET mutation, serum calcitonin concentrations, plasma metanephrines, and imaging methods such as ultrasound, CT, MRI, and nuclear scanning to determine the presence of tumors and extent of metastasis. Detection with early diagnosis using genetic screening for prophylactic thyroidectomy drastically improves patient results and eliminates dangers to mortality.

The increasing incidence of Multiple Endocrine Neoplasia Type 2 (MEN2), caused by inherited genetic mutations in the RET proto-oncogene, is a key driver of market expansion. As MEN2 is an autosomal dominant condition, family history carriers have a high likelihood of developing the disease, for which early genetic testing and prophylactic treatments are required. Growing recognition of predictive genetic testing has contributed to a boom in early diagnoses, allowing for timely prophylactic thyroidectomy, especially in high-risk RET mutation children. Increased use of targeted therapies like selective RET inhibitors pralsetinib and selpercatinib has also radically shifted the treatment landscape by providing improved and less toxic options compared to conventional chemotherapy. The progression in radioactive imaging and precision medicine is also stimulating market growth through the ability to detect tumors with greater accuracy and tailored treatment schemes. Additionally, clinical trials currently underway for emerging therapies against RET mutations and combination therapies are expected to further propel the market. The transition toward personalized medicine, enhanced screening campaigns, and emerging therapeutic strategies are expected to propel market growth through the forecast period.

IMARC Group's new report provides an exhaustive analysis of the multiple endocrine neoplasia type 2 market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for multiple endocrine neoplasia type 2 and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple endocrine neoplasia type 2 market in any manner.

Key Highlights:

• MEN2 affects approximately 1 in 30,000–35,000 individuals globally, making it a rare inherited endocrine disorder.
• Caused by RET proto-oncogene mutations, MEN2 follows an autosomal dominant pattern, giving offspring a 50% inheritance risk.
• MEN2A involves medullary thyroid carcinoma, pheochromocytomas, and hyperparathyroidism, while MEN2B includes aggressive MTC, mucosal neuromas, and a marfanoid body habitus.
• Symptoms include neck lumps, difficulty swallowing (MTC), hypertension, excessive sweating (pheochromocytomas), and kidney stones, osteoporosis (hyperparathyroidism).
• Genetic testing enables early detection; prophylactic thyroidectomy and regular monitoring of adrenal and parathyroid tumors are key preventive measures.

Time Period of the Study

• Base Year: ​2024​
• Historical Period: 2019-2024
• Market Forecast: ​2025-2035​

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the multiple endocrine neoplasia type 2 market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the multiple endocrine neoplasia type 2 market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current multiple endocrine neoplasia type 2 marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the multiple endocrine neoplasia type 2 market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in ​2024​ and how are they expected to perform till 2035?
• What was the country-wise size of the multiple endocrine neoplasia type 2 market across the seven major markets in ​2024​ and what will it look like in 2019-2024?
• What is the growth rate of the multiple endocrine neoplasia type 2 market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (​​2035​​) of multiple endocrine neoplasia type 2 across the seven major markets?
• What is the number of prevalent cases (​​2035​​) of multiple endocrine neoplasia type 2 by age across the seven major markets?
• What is the number of prevalent cases (​​2035​​) of multiple endocrine neoplasia type 2 by gender across the seven major markets?
• How many patients are diagnosed (​​2035​​) with multiple endocrine neoplasia type 2 across the seven major markets?
• What is the size of the multiple endocrine neoplasia type 2 patient pool (2019-2024​) across the seven major markets?
• What would be the forecasted patient pool (​2025-2035​) across the seven major markets?
• What are the key factors driving the epidemiological trend of multiple endocrine neoplasia type 2?
• What will be the growth rate of patients across the seven major markets?

Multiple Endocrine Neoplasia Type 2: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for multiple endocrine neoplasia type 2 drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple endocrine neoplasia type 2 market?
• What are the key regulatory events related to the multiple endocrine neoplasia type 2 market?
• What is the structure of clinical trial landscape by status related to the multiple endocrine neoplasia type 2 market?
• What is the structure of clinical trial landscape by phase related to the multiple endocrine neoplasia type 2 market?
• What is the structure of clinical trial landscape by route of administration related to the multiple endocrine neoplasia type 2 market?